Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - WEIKANG BIO-TECHNOLOGY GROUP CO., INC. | Financial_Report.xls |
| EX-32.2 - EXHIBIT 32.2 - WEIKANG BIO-TECHNOLOGY GROUP CO., INC. | v330115_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - WEIKANG BIO-TECHNOLOGY GROUP CO., INC. | v330115_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - WEIKANG BIO-TECHNOLOGY GROUP CO., INC. | v330115_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - WEIKANG BIO-TECHNOLOGY GROUP CO., INC. | v330115_ex31-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
Amendment No. 1
(Mark One)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2012
or
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _______ to _______
Commission File Number: 333-165684
WEIKANG BIO-TECHNOLOGY GROUP CO., INC.
(Exact name of small business issuer as specified in its charter)
| Nevada | 22-2816569 | |
|
(State or other jurisdiction of incorporation or organization) |
(IRS Employer identification No.) |
No. 365 Chengde Street, Daowai District, Harbin
Heilongjiang Province, People’s Republic of China 150020
(Address of principal executive offices)
(86) 451- 88355530
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ¨ | Accelerated filer ¨ |
| Non-accelerated filer ¨ (Do not check if a smaller reporting company) | Smaller reporting company x |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes ¨ No x
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:
Check whether the registrant filed all documents and reports required to be filed by Section l2, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. Yes ¨ No ¨
APPLICABLE ONLY TO CORPORATE ISSUERS:
State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 35,128,358 shares of common stock, $.00001 par value, were outstanding as of December 5, 2012.
Explanatory Note
The purpose of this Amendment No. 1 to WEIKANG BIO-TECHNOLOGY GROUP CO., INC. Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, filed with the Securities and Exchange Commission on December 10, 2012 (the “Form 10-Q”), is solely to amend Statement of Stockholders’ Equity in Exhibit 101 to the Form 10-Q. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).
No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.
Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
Item 6. Exhibits.
(a) Exhibits
| 2.1 | Share Exchange Agreement among Expedition Leasing Inc. (“Expedition Leasing”), certain stockholders of Expedition Leasing, Sinary Bio-Technology Holding Group, Inc. (“Sinary”) and the sole stockholder of Sinary dated December 7, 2007 (1) | ||
| 2.2 | Equity Transfer Agreement between Sinary and the owners of 100% of the registered equity of Heilongjiang Weikang Bio-Technology Group Co., Ltd. Dated October 25, 2007 (1) | ||
| 2.3 | Agreement and Plan of Merger dated as of June 4, 2008 between Expedition Leasing and Weikang (2) | ||
| 3.1 | Articles of Incorporation of Weikang (2) | ||
| 3.2 | Bylaws of Weikang (2) | ||
| 4.1 | Form of Series A and B Common Stock Warrant (3) | ||
| 4.2 | Form of Series C Warrant (4) | ||
| 4.3 | Form of Series D Warrant (4) | ||
| 4.4 | Form of warrants issued to the placement agents (4) | ||
| 4.5 | Form of Subscription Agreement, by and between Weikang Bio-Technology Group Company, Inc. and the investors. (4) | ||
| 4.6 | Form of Registration Rights Agreement, by and between Weikang Bio-Technology Group Company, Inc. and the investors. (4) | ||
| 4.7 | Form of Lock-Up Agreement (4) | ||
| 31.1 | Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* | ||
| 31.2 | Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* | ||
| 32.1 | Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* | ||
| 32.2 | Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* | ||
| 101.INS | XBRL INSTANCE DOCUMENT** | ||
| 101.SCH | XBRL TAXONOMY EXTENSION SCHEMA** | ||
| 101.CAL | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE** | ||
| 101.DEF | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE** | ||
| 101.LAB | XBRL TAXONOMY EXTENSION LABEL LINKBASE** | ||
| 101.PRE | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE** | ||
(1) Incorporated by reference from the Company’s Form 8-K filed with the SEC on December 10, 2007.
(2) Incorporated by reference from the Company’s Schedule 14C filed with the SEC on May 14, 2008.
(3) Incorporated by reference from the Company’s Form 8-K filed with the SEC on January 26, 2010.
(4) Incorporated by reference from the Company’s Form 8-K filed with the SEC on December 8, 2010
* Filed herewith.
** Furnished herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| WEIKANG BIO-TECHNOLOGY GROUP COMPANY, INC. | |||
| Dated: December 11, 2012 | By: | /s/ Yin Wang | |
| Yin Wang | |||
| Chief Executive Officer | |||
| (Principal Executive Officer) | |||
| By: | /s/ Baolin Sun | ||
| Baolin Sun | |||
| Chief Financial Officer | |||
| (Principal Accounting & Financial Officer) | |||